Korro Bio KRRO
NASDAQ KRRO
$12.96 -0.99 (-7.10%)
At close: Aug 20, 2026 · 4:00 PM EDT

Korro Bio (KRRO) Receivables - Net (2018 - 2025)

Korro Bio's (KRRO) quarterly Receivables - Net came in at $969000.0 in Q4 2025, down 42.87% YoY from $1.7 million in Q4 2024, and up 18.17% on a QoQ basis from $820000.0 in Q3 2025.

Korro Bio (KRRO) Receivables - Net (2018 - 2025) Analysis & Trends

Korro Bio (KRRO) has 5 years of Receivables - Net data on file, last reported at $969000.0 in Q4 2025.

  • Quarterly Receivables - Net fell 42.87% year-over-year to $969000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $969000.0 (down 42.87% YoY) and the FY2025 annual result came in at $1.0 million, down 41.18% from the prior year.
  • Receivables - Net climbed to $969000.0 in Q4 2025, from $820000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $10.0 million in Q3 2024 to a low of $820000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 Korro Bio 228.60 Mn 113.56 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 969,000.00
Dec 31, 2025 969,000.00
Sep 30, 2025 820,000.00
Sep 30, 2025 820,000.00
Jun 30, 2025 1.10 Mn
Jun 30, 2025 1.10 Mn
Mar 31, 2025 1.92 Mn
Mar 31, 2025 1.92 Mn
Dec 31, 2024 1.70 Mn
Dec 31, 2024 1.70 Mn
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn
Mar 31, 2020 246,000.00
Mar 31, 2020 246,000.00
Dec 31, 2019 805,000.00
Dec 31, 2019 805,000.00
Sep 30, 2019 408,000.00
Sep 30, 2019 408,000.00
Dec 31, 2018 161,000.00
Dec 31, 2018 161,000.00